Tau抗体;Tau Antibody—艾普蒂

+ +

•  

   

     Cross reactivityMicrotiter wells were coated with recombinant human Tau and phosphorylated Tau proteins. P15794 was used as primary antibody and peroxidase conjugated goat anti- mouse IgG was used as the secondary antibody.Result: P15794 can react with human Tau and phosphorylated Tau proteins.    

  
  

•  

   

     Result: P15794 can detect recombinant human Tau by Western blotting.    

  
  

•  

   

     IHC-P analysis of cerebral cortex tissue by Tau antibody (P15794) IHC-P was performed using sections of the formalin-fixed paraffin-embedded cerebral cortex tissue;Result: Neuropil are positively stained.    

  
  

Tau antibodies are essential tools in neuroscience research and diagnostics, primarily targeting the tau protein—a microtubule-associated protein critical for stabilizing neuronal microtubules in the brain. In healthy neurons, tau regulates axonal transport and structural integrity. However, in neurodegenerative diseases termed "tauopathies," including Alzheimer’s disease (AD), tau becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs), contributing to neuronal dysfunction and cognitive decline.

Tau antibodies are designed to detect specific epitopes or pathological forms of tau. For example, phosphorylation-specific antibodies (e.g., AT8. AT100) identify disease-associated hyperphosphorylated tau, while conformation-specific antibodies (e.g., MC1) recognize misfolded tau. Others target isoforms (3R/4R tau) or truncation sites. These antibodies are widely used in immunohistochemistry, Western blotting, and ELISA to study tau pathology in postmortem brain tissues, animal models, or biofluids like cerebrospinal fluid (CSF).

Clinically, tau antibodies underpin biomarker assays for AD diagnosis, such as CSF p-tau181 or p-tau217. which correlate with NFT burden. Therapeutic tau-targeting antibodies, like semorinemab or gosuranemab, are in clinical trials to clear pathological tau or block its spread, though efficacy remains under evaluation. Challenges include ensuring blood-brain barrier penetration and minimizing off-target effects. Overall, tau antibodies bridge basic research, diagnostics, and emerging therapies in tau-related neurodegeneration.

(Word count: 247)